Intelligence Profile
Safety Profile
Recaticimab Safety Profile
Known Side Effects:
Recaticimab, as a PCSK9 monoclonal antibody, has been generally well-tolerated in clinical trials. Common side effects reported include mild injection site reactions, such as redness, swelling, or discomfort. Additionally, some patients have experienced headache and nasopharyngitis. While these effects are typically mild and self-limiting, monitoring is recommended.
Contraindications:
There is limited direct evidence regarding specific contraindications for recaticimab. As with other monoclonal antibodies, it is contraindicated in patients with known hypersensitivity to the drug or its components.
Drug Interactions:
Current evidence does not highlight any significant drug interactions specific to recaticimab. However, as with any new therapeutic agent, caution should be exercised when it is used in combination with other lipid-lowering therapies until further studies are conducted.
Populations to Avoid Use:
- Pregnant and Nursing Women: There is insufficient data on the effects of recaticimab during pregnancy or lactation. Use is not recommended unless the potential benefits justify the potential risk to the fetus or infant.
- Pediatrics: Safety and efficacy in pediatric populations have not been established, warranting caution.
- Severe Hepatic Impairment: While not specifically contraindicated, individuals with significant liver dysfunction should use recaticimab with caution due to the pharmacological mechanisms of PCSK9 inhibitors.
Overall, while the evidence covers some safety aspects of recaticimab, further post-marketing surveillance and studies are needed to establish a comprehensive safety profile, especially for long-term use and in varied patient demographics.
Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.